A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians

J Am Coll Cardiol. 1995 Feb;25(2):387-94. doi: 10.1016/0735-1097(94)00370-6.

Abstract

Objectives: This study evaluated whether increased intake of fish oils (eicosapentaenoic and docosahexaenoic acids) might reduce the risk of coronary heart disease.

Background: Observational and clinical studies have suggested that increased intake of fish oils, as reflected in plasma levels of fish oils, may reduce the risk of myocardial infarction.

Methods: A nested case-control study was conducted among the 14,916 participants in the Physicians' Health Study with a sample of plasma before randomization. Each participant with myocardial infarction occurring during the first 5 years of follow-up was matched by smoking status and age with a randomly chosen control participant who had not developed coronary heart disease.

Results: Mean levels of fish oils (with 95% confidence interval [CI] for paired differences and p values) in case and control participants, expressed as percent of total fatty acids, were, for eicosapentaenoic acid, 0.26 versus 0.25 (95% CI -0.03 to 0.05, p = 0.70) in cholesterol esters and 0.56 versus 0.54 (95% CI -0.04 to 0.09, p = 0.44) in phospholipids, and for docosahexaenoic acid, 0.23 versus 0.24 (95% CI -0.07 to 0.04, p = 0.64) in cholesterol esters and 2.22 versus 2.14 (95% CI -0.10 to 0.27, p = 0.36) in phospholipids. Results adjusted for major cardiovascular risk factors showed a very similar lack of association between fish oil levels and the incidence of myocardial infarction.

Conclusions: These results indicate no beneficial effect of increased fish oil consumption on the incidence of a first myocardial infarction. However, the effect of very high levels of fish oils could not be evaluated.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Aspirin / therapeutic use
  • Carotenoids / therapeutic use
  • Case-Control Studies
  • Cholesterol Esters / blood
  • Double-Blind Method
  • Fatty Acids, Omega-3 / administration & dosage
  • Fatty Acids, Omega-3 / blood*
  • Fish Oils / administration & dosage
  • Fish Oils / blood*
  • Humans
  • Incidence
  • Logistic Models
  • Male
  • Middle Aged
  • Myocardial Infarction / blood
  • Myocardial Infarction / epidemiology*
  • Myocardial Infarction / prevention & control
  • Phospholipids / blood
  • Physicians*
  • Prospective Studies
  • Risk Factors
  • beta Carotene

Substances

  • Adjuvants, Immunologic
  • Cholesterol Esters
  • Fatty Acids, Omega-3
  • Fish Oils
  • Phospholipids
  • beta Carotene
  • Carotenoids
  • Aspirin